News

Filter

Current filters:

Genmab

1 to 9 of 32 results

Genmab reports nine month interim results, including $31 million revenue increase on 2013

Genmab reports nine month interim results, including $31 million revenue increase on 2013

06-11-2014

Danish biotech company Genmab has reported its nine-month interim results, including an increase in revenue…

BiotechnologydaratumumabDenmarkDuoBodyFinancialGenmabOfatumumab Injection

Genmab transfers its ofatumumab collaboration from GSK to Novartis

Genmab transfers its ofatumumab collaboration from GSK to Novartis

03-11-2014

Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and…

DenmarkGenmabGSKNovartisOfatumumab InjectionOncologyPharmaceuticalResearch

Genmab gets latest milestone in daratumumab Janssen collaboration

Genmab gets latest milestone in daratumumab Janssen collaboration

24-10-2014

Danish biotech company Genmab has reached the fourth milestone in its daratumumab collaboration with…

daratumumabDenmarkGenmabJanssenOncologyPharmaceuticalResearch

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

GSK and Genmab announce positive interim results for ofatumumab Phase III

GSK and Genmab announce positive interim results for ofatumumab Phase III

01-08-2014

UK Pharma major GlaxoSmithKline and Danish biotechnology company Genmab have said that an interim analysis…

Chronic lymphocytic leukemiaDenmarkGenmabGSKOfatumumabOfatumumab InjectionOncologyPharmaceuticalRafael AmadoResearchUK

EU approval for GSK and Genmab’s Arzerra as first-line CLL therapy

EU approval for GSK and Genmab’s Arzerra as first-line CLL therapy

03-07-2014

The European Commission has granted marketing authorization for a new indication for the use of UK pharma…

ArzerraEuropeGenmabGlaxoSmithKlineOncologyPharmaceuticalRegulation

GSK and Genmab’s ofatumumab disappoints in Ph III CLL study

28-06-2014

UK pharma giant GlaxoSmithKline and Danish partner Genmab have revealed that the Phase III study of…

GenmabGlaxoSmithKlineOfatumumab InjectionOncologyPharmaceutical

GSK and Genmab reveal disappointing Ph III data with ofatumumab + chemo in B-cell lymphoma

20-05-2014

UK Pharma major GlaxoSmithKline and Denmark’s Genmab revealed yesterday that the Phase III ORCHARRD…

GenmabGlaxoSmithKlineOfatumumab InjectionOncologyPharmaceuticalResearch

1 to 9 of 32 results

COMPANY SPOTLIGHT

Menarini

Back to top